Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NGM707 |
Trade Name | |
Synonyms | NGM-707|NGM 707 |
Drug Descriptions |
NGM707 is a monoclonal antibody with dual specificity to both ILT2 and LILRB2 (ILT4), which inhibits ligand binding including both classical and non-classical MHC-I molecules, potentially resulting in the activation of an immune cell response (Cancer Res 2021;81(13_Suppl):Abstract nr LB156). |
DrugClasses | LILRB2 Antibody 12 |
CAS Registry Number | NA |
NCIT ID | C180904 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
NGM707 | NGM707 | 0 | 1 |
NGM707 + Pembrolizumab | NGM707 Pembrolizumab | 0 | 1 |